Ipsen

Related Companies

• Marchesini Group
• Rentschler Biopharma SE
• 3P innovation

Related Content

Somatuline Autogel receives Japanese approval for tumour treatment

David Meek to join Ipsen as Chief Executive

Ipsen to use Dassault Systemes' software to support drug discovery

Ipsen and Exelixis enter into exclusive licensing agreement for cancer therapy cabozantinib

Ipsen acquires OctreoPharm Sciences for €50m

Ipsen signs R&D agreement with Harvard University

Ipsen enters into option agreement to buy Canbex Therapeutics

Ipsen strengthens neurology capabilities with acquisition of Syntaxin

Harlan and Ipsen enter into drug development services agreement

Patent applications published 22 June 2011

Patent applications published 23 March 2011

Patent applications published 9 February 2011

Drug licensing deals in 2010

Russell Greig becomes Syntaxin chairman